KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Receivables for 13 consecutive years, with $8.6 million as the latest value for Q1 2025.

  • Quarterly Receivables rose 938.3% to $8.6 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Mar 2025, up 938.3% year-over-year, with the annual reading at $2.9 million for FY2024, 236.16% up from the prior year.
  • Receivables for Q1 2025 was $8.6 million at Xenon Pharmaceuticals, up from $2.9 million in the prior quarter.
  • The five-year high for Receivables was $8.6 million in Q1 2025, with the low at $805000.0 in Q3 2023.
  • Average Receivables over 5 years is $2.5 million, with a median of $2.5 million recorded in 2022.
  • The sharpest move saw Receivables tumbled 67.57% in 2023, then skyrocketed 938.3% in 2025.
  • Over 5 years, Receivables stood at $2.8 million in 2021, then plummeted by 64.34% to $986000.0 in 2022, then dropped by 11.36% to $874000.0 in 2023, then surged by 236.16% to $2.9 million in 2024, then soared by 194.38% to $8.6 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $8.6 million, $2.9 million, and $938000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.